Section Arrow
IBRX.NASDAQ
- ImmunityBio
Quotes are at least 15-min delayed:2026/03/25 09:35 EDT
Regular Hours
Last
 7.845
+0.43 (+5.80%)
Day High 
7.89 
Prev. Close
7.415 
1-M High
12.43 
Volume 
2.29M 
Bid
7.83
Ask
7.85
Day Low
7.45 
Open
7.75 
1-M Low
6.54 
Market Cap 
7.62B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.36 
20-SMA 8.8 
50-SMA 7.35 
52-W High 12.43 
52-W Low 1.83 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.38/0.04
Enterprise Value
8.13B
Balance Sheet
Book Value Per Share
-0.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
113.29M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TERNTerns Pharmaceuticals52.61+2.61+5.22%-- 
AVXLAnavex Life Sciences Corp3.095-1.095-26.13%-- 
IBRXImmunityBio7.865+0.45+6.07%-- 
SRPTSarepta Therapeutics21.21+3.6+20.44%-- 
OCGNOcugen2.045+0.125+6.51%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.